Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed
By Matthew Perlman · February 18, 2026, 8:49 PM EST
A Virginia federal court found that Sandoz Inc. should have brought its claims accusing Amgen of blocking competition for Enbrel in a previous patent dispute over the blockbuster autoimmune disease treatment....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login